LDLR and diabetic kidney disease: To further strengthen the postulate that APOC3 plays a role in DKD and that it is liver-derived APOC3, we treated BTBR WT and OB mice with a newer generation of the APOC3 ASO, which has a higher hepatic specificity because of an N-acetylgalactosamine (GalNAc) modification, allowing for a lower dose, together with the LDLR ASO.